AbbVie: Phase 3 trial of leukemia combo met primary endpoint

AbbVie (ABBV) announced positive results from CLL14, a Phase 3, randomized clinical trial evaluating venetoclax plus obinutuzumab versus obinutuzumab plus chlorambucil, a standard of care, in patients with chronic lymphocytic leukemia and coexisting medical conditions who have not received a prior treatment. The study met its primary endpoint of investigator-assessed progression-free survival with a 12-month fixed duration of treatment. Preliminary analysis suggests the safety profile observed in the combination of venetoclax plus obinutuzumab is consistent with the known safety profile of each medicine alone.Results from the CLL14 trial will be presented at a future medical meeting. Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group (RHHBY), in the U.S. and by AbbVie outside of the U.S.
https://thefly.com/landingPageNews.php?id=2814811